



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

NIH National Cancer Institute at the National Institutes of Health

OMB# 0925-0046-09  
Exp. Date: 05/31/2016

### Introduction

The National Cancer Institute (NCI) would like to know about your experiences with the Experimental Therapeutics Clinical Trials Network (ETCTN) over the past grant year (April 2014 - March 2015).

Your input will help NCI assess and refine the ETCTN processes and identify areas for improvement.

The survey will ask questions about ETCTN processes and activities and trial portfolio. It should take approximately 10 minutes to complete.

Your responses are confidential and all results will be reported in the aggregate. Your participation and responses will have no bearing on your ETCTN grant, or any future interactions with NCI.

We thank you for your assistance!

To continue and begin the survey, click the "Next" button below.

Next >

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

NIH National Cancer Institute at the National Institutes of Health

OMB# 0925-0046-09  
Exp. Date: 05/31/2016

### Privacy Statement and Consent

Collection of this information is authorized by The Public Health Service Act, Section 411 (42 USC 285a). Participation is voluntary and there are no penalties for not participating or withdrawing from the study at any time. The information collected in this study will be kept private to the extent provided by law. Names and other identifiers will not appear in any report of the study. Information provided will be combined for all study participants and reported as summaries. You are being contacted by User-Centered Design, Inc. via email to complete this instrument so that we can gain feedback from you on your experiences and recommendations regarding the implementation of the ETCTN program.

Please click the "Next" button if you consent to taking this survey.

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 208927974, ATTN: PRA (0925-0046-09). Do not return the completed form to this address.

Next >

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)

**Unsolicited Letter of Intent (LOI) Process for ETCTN Trials**

*This set of questions asks you about your opinion of the **unsolicited** letter of intent (LOI) process.*

1. How aware are you of the **unsolicited LOI process** used in the ETCTN?

**Not very  
aware**





**Very  
aware**

2. How satisfied are you with the **unsolicited LOI process** in terms of ...

	<b>Not very satisfied</b>				<b>Very satisfied</b>	<b>Don't know</b>
Transparency of the unsolicited LOI submission process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Transparency of the unsolicited LOI review process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Efficiency of the unsolicited LOI process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Communication received from NCI about the unsolicited LOI process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Number of drugs available to investigators to develop quality LOIs	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Clarity of which drugs are available for unsolicited LOIs	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

2a. Please describe any changes NCI could make to increase your satisfaction with the unsolicited LOI process.

[< Back](#)

[Save and Continue >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



Opt-out of survey



15% Complete

3. In the past grant year of the ETCTN (April 2014 - March 2015), which of the following steps have you or others at your site participated in for **unsolicited LOIs**? (Select all that apply.)

	Submitted an unsolicited LOI	Had an unsolicited LOI approved	Submitted a protocol	Had a protocol reviewed	Activated a protocol
I have ...	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A colleague of mine has ...	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)

**Note:** 3a appears conditionally, populated with any items selected for "I have..." in Q3.



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



Opt-out of survey



20% Complete

3a. What is your level of satisfaction for these phases of the unsolicited LOI process that you were involved with?

	Not very satisfied				Very satisfied
Submitted an unsolicited LOI	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
LOI review process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Submitted a protocol	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol review process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Activated a protocol	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)




Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



Opt-out of survey



**Project Team Member Applications and Drug Development Plan to Develop ETCTN Trials**

*This set of questions asks you about your opinion of the Drug Development Project Team Member Application DDP/ (PTMA) process used to submit LOIs and protocols.*

4. How aware are you of the Drug Development PTMA process (DDP/PTMA) used in the ETCTN?

Not very aware

Very aware

5. How much do you agree or disagree with the following statements about the DDP/PTMA process?

The DDP/PTMA process ...	Strongly disagree	Disagree	Agree	Strongly agree	Don't know
streamlines the development of early phase trials.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
encourages multidisciplinary teams.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
is a fair process to develop early phase trials.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
has reduced my workload in comparison to other early phase trial processes.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Overall, I am satisfied with the DDP/PTMA process.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)




Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

NIRX National Cancer Institute at the National Institutes of Health

Opt-out of survey



6. In the past grant year of the ETCTN (April 2014 - March 2015), which of the following steps have you or others at your site participated in for the DDP/PTMA process? (Select all that apply.)

	Submitted a Project Team Member Application (PTMA)	Participated in a Drug Development Plan	Been a Co-Leader for a Drug Development Plan	Submitted a letter of intent (LOI)	Submitted a protocol	Activated a protocol
I have ...	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Others at my site have ...	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)

**Note:** 6a and 6b appear conditionally; 6a is populated with any items selected for "I have..." in Q6. 6b appears if 6a appears.



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



Opt-out of survey



6a. What is your level of satisfaction for each phase of the DDP/PTMA process in which you were involved?

	Not very satisfied				Very satisfied
PTMA submission process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Development of drug plan	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Co-leading drug development plan	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Letter of intent (LOI) submission	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol submission	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol activation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

6b. Please describe any changes NCI could make to increase your satisfaction with the DDP/PTMA process.

Text input area for describing changes to increase satisfaction.

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com




Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



Opt-out of survey



Opening ETCTN Trials

7. Looking at the list of ETCTN protocols activated during the program's first year, please indicate whether or not your site has opened each.

	Have Opened	In Process of Opening	Have Not Opened
Protocol 1	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol 2	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol 3	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
... Protocol n	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)

Note: 7a appears conditionally if "have not opened" is selected for any protocol in Q7.



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



Opt-out of survey



7a. For what reasons have you not opened available ETCTN trials?

Text input area for reasons for not opening trials.

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



Opt-out of survey



8. Based on your experiences in the past grant year, how satisfied are you with the following aspects of opening an ETCTN trial at your center?

	Not very satisfied				Very satisfied
Communication received about trial while it was in the pipeline	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Communication received from NCI during the process to open a trial	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Time required to open a trial	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Workload required to open a trial	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Time required to maintain a study	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Interactions with CTSU	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Interactions with CIRB	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Interactions with Theradex	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

8a. Please describe any changes NCI could make to increase your satisfaction with opening ETCTN trials at your site.

Text input area for describing changes NCI could make.

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)




**ETCTN Trial Portfolio**

9. ETCTN protocols are intended to be innovative and are not to be duplicative of research funded by industry or other resources.

Below is a list of ETCTN protocols that were activated during the past grant year. For each protocol, please indicate whether or not you consider the trial to be answering an important scientific question?

	Not important scientific question				Important scientific question	Don't know
Protocol 1	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol 2	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol 3	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
... Protocol n	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

10. Looking at the list of trials above, to what degree are you satisfied with the overall portfolio of activated protocols in the ETCTN?

**Not satisfied**




**Very satisfied**

[< Back](#)
[Save and Continue >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



Opt-out of survey

60% Complete

11. Below is a list of considerations about the ETCTN portfolio.

Please indicate how satisfied you are with each topic with respect to the ETCTN portfolio of trials.

	Not satisfied				Very satisfied
Number of trials in portfolio	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Number of trials available for my center to open	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Representation of therapeutic classes	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Balance between scientific areas	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lack of duplication with research conducted by industry or other sources	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Importance of scientific questions addressed	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Integration of preclinical findings	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

11a. Please describe any changes NCI could make to increase your satisfaction with the portfolio of trials.

Empty text box for user input.

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)

12. What changes would you like to see in the emphasis of different scientific areas in trials in the ETCTN portfolio?

	Less emphasis	About the same emphasis	More emphasis
Angiogenesis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Immunotherapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Molecular characterizations of tumor features	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Organ dysfunction	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Organ dysfunction	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmacokinetics	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Signal transduction	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

12a. If other, please describe:

[< Back](#)

[Save and Continue >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



Opt-out of survey



Network Readiness and Satisfaction with the ETCTN

13. Overall, how ready do you believe each of the groups below were to participate in the ETCTN at the beginning of the grant year in April 2014?

Table with 7 columns: Not ready, (5 unlabeled), Very read, Don't know. Rows: Your center, The ETCTN overall.

14. Overall, how ready do you believe each of the groups below is now to participate in the ETCTN?

Table with 7 columns: Not ready, (5 unlabeled), Very read, Don't know. Rows: Your center, The ETCTN overall.

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

NIH National Cancer Institute at the National Institutes of Health

Opt-out of survey

75% Complete

15. Please review the statements below and indicate how much you agree or disagree with each.

	Strongly disagree				Strongly agree
There are enough trials activated in the ETCTN to reach our center's accrual goals.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Overall I am satisfied with the progress made over the ETCTN's first year.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I expect most concerns that I have with the ETCTN in the first year will get worked out in the remaining years of the grant.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
There is strong collaboration among the different centers in the ETCTN.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The collaboration with other centers in the ETCTN is productive.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
My center has a team-based approach for generating ideas for early phase trials.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Our center has made substantial changes to its processes to accommodate the ETCTN.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The ETCTN opens up career opportunities for junior investigators at our center.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Overall, the NCI leadership is responsive to the ETCTN grantees' needs and input.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)

16. Below is a list of potential benefits to be achieved via the ETCTN network.

Please indicate if you think that each of the potential benefits is:

- More likely to occur with *ETCTN trials*,
- More likely to occur with *other investigator-initiated trials at your center*  
OR
- Equally likely to occur with *other investigator-initiated trials and with ETCTN trials*

	More Likely to Occur With <b>ETCTN</b> Trials at my Center	More Likely to Occur With <b>Other</b> Investigator-Initiated Trials at my Center	Likely to Occur <b>Equally</b> With Other Investigator-Initiated Trials <b>AND</b> ETCTN Trials
Obtain IRB approval quickly.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Activate trials quickly at my center.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Participate in scientifically important trials.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Access drugs early in their development.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Participate in trials that will help advance my career.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Enroll patients to trials at the projected accrual rate.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Provide my patients access to a wide variety of early phase clinical trial options.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Collaborate with investigators at other centers.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Collaborate with researchers from other disciplines.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

[< Back](#)
[Save and Continue >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



Opt. out of survey

85% Complete

Social Network Collaborations

We would like to learn more about your work with other researchers that are involved in the ETCTN.

17. Please look at the list of ETCTN organization members below and indicate a "yes" for those you had direct collaboration with over the past year (either developing protocols or opening trials).


Table with 3 columns: ETCTN Lead Academic Organizations and Affiliates, Yes, No. Lists various cancer centers and institutes with radio buttons for selection.

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



**Demographics**

*The next set of questions asks about your background and experience with cancer research.*

18. Please indicate your sex:

- Female
- Male

19. Please indicate your ethnicity:

- Hispanic or Latino
- Not Hispanic or Latino

20. Please indicate your race (mark one or more of the following):

- American Indian or Alaska Native
- Asian
- Black or African American
- Native Hawaiian or Other Pacific Islander
- White

21. Please indicate your scientific specialty?

22. How long have you been involved with ...

	1-5 years	6-10 years	11-15 years	16-20 years	20+ years
Early phase clinical trials	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cancer research	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Your center	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

23. Other than NCI, where have you received funding for cancer research? (Select all that apply.)

- Pharmaceutical industry
- Pharmaceutical industry
- Biotechnology companies
- Department of Veteran Affairs
- Department of Defense

[< Back](#)

[Save and Continue >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)





*Team Driven. Cancer Therapy Focused.*

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

[Opt-out of survey](#)

95% Complete

24. Do you have any final comments about ETCTN that you would like to share?

[< Back](#)

[Submit Survey >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)



*Team Driven. Cancer Therapy Focused.*

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

[Opt-out of survey](#)

100% Complete

**Thank you for completing this survey!**

Your answers have been submitted securely.

We appreciate your feedback regarding the ETCTN.  
Your feedback will help us refine the ETCTN and identify areas for improvement.

If you would like a summary of the findings after the survey closes,  
please send an email to [JenniferHuang@westat.com](mailto:JenniferHuang@westat.com)

**You may now close this window.**

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at [survey@user-centereddesign.com](mailto:survey@user-centereddesign.com)